Pituch-Noworolska A, Gawlicka M, Balwierz W
Department of Clinical Immunology and Microbiology, Polish-American Childrens Hospital, Kraków.
Pol J Pathol. 1995;46(2):77-82.
Multidrug resistance (MDR) is associated with expression of P-glycoprotein in the malignant cells as the one of known mechanisms for this phenomenon. The isolated blast cells of 60 patients with acute leukemia and non-Hodgkin's lymphoma (NHL) were assayed for the expression of P-glycoprotein (P-170) with MRK16 antibody. The frequency of P-170 expression was studied in the different subtypes of leukemia and NHL based on blasts phenotype. In acute leukemia and lymphoma with B cell lineage of blast cells the percentage of P-170 positive samples was 41.3%, in the non-lymphoblastic leukemia--35.3% and the T cell lineage--75% of P-170 positive samples. The expression of P-170 molecule was associated with: 1. T cell origin of blasts, 2. lymphoma form of proliferation. The P-170 assay selects the group of patients with higher risk of drug resistance for modified therapy.
多药耐药（MDR）与恶性细胞中P-糖蛋白的表达有关，这是该现象已知的机制之一。用MRK16抗体检测了60例急性白血病和非霍奇金淋巴瘤（NHL）患者分离的原始细胞中P-糖蛋白（P-170）的表达。基于原始细胞表型，研究了白血病和NHL不同亚型中P-170表达的频率。在原始细胞为B细胞系的急性白血病和淋巴瘤中，P-170阳性样本的百分比为41.3%，在非淋巴细胞白血病中为35.3%，在T细胞系中为75%。P-170分子的表达与以下因素有关：1. 原始细胞的T细胞起源；2. 淋巴瘤增殖形式。P-170检测可为改良治疗筛选出耐药风险较高的患者群体。
